BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 1, 2026
Home » mutations

Articles Tagged with ''mutations''

3D image showing the human protein KRAS interacting with RAF1
Cancer

KRAS allosteric mapping may open new therapeutic opportunities

Dec. 22, 2023
By Xavier Bofill Bruna
In an article published on Dec. 18, 2023, in Nature, researchers from the Centre for Genomic Regulation in Barcelona (Spain) and Wellcome Sanger Institute in Hinxton (U.K.) reported achieving a milestone regarding KRAS targeting in cancer. The team quantified the impact of >26,000 KRAS variants and how these mutations affected protein folding and its interaction with the six main effectors – RAF1, PIK3CG, RALGDS, SOS1, K27 and K55.
Read More
Cells and DNA helix
Genetic/Congenital

‘A trillion in each of us’: Flagship-backed Quotient takes on somatic genomics

Nov. 29, 2023
By Jennifer Boggs
Launching a company based on knowledge that “the fundamental principle that most people hold to be true is off by a trillion” is a rare opportunity, said Jake Rubens, co-founder and president of Quotient Therapeutics Inc., a company that emerged from stealth this week, backed by two years of platform development and a $50 million investment from Flagship Pioneering.
Read More
Cells and DNA helix
Newco news

‘A trillion in each of us’: Flagship-backed Quotient takes on somatic genomics

Nov. 22, 2023
By Jennifer Boggs
Launching a company based on knowledge that “the fundamental principle that most people hold to be true is off by a trillion” is a rare opportunity, said Jake Rubens, co-founder and president of Quotient Therapeutics Inc., a company that emerged from stealth this week, backed by two years of platform development and a $50 million investment from Flagship Pioneering.
Read More
Cross section of brain
Biomarkers

Multi-omic profiling unveils mutated genes in malformations of cortical development

Jan. 17, 2023
Malformations of cortical development (MCD) are a group of neurodevelopmental disorders characterized by malformation of cortical structures, which often lead to epilepsy, and include cortical dysplasia (FCD), hemimegalencephaly (HME) and tuberous sclerosis complex (TSC).
Read More
Woman in crowd with anxiety
Biomarkers

SORCS3 gene found as a susceptibility gene for panic disorder

Oct. 18, 2022
Panic disorder is defined by recurrent and...
Read More
Illustration of brain, DNA
Biomarkers

CAPRIN1 P512L variant tied to early-onset ataxia neurodegenerative disorder

Sep. 30, 2022
Cell cycle-associated protein 1 (CAPRIN1) is an ubiquitously expressed protein, the levels of which are usually high in tissues with an elevated cell turnover; it is also abundant in the brain, where it regulates the transport and translation of synaptic protein mRNA.
Read More
Red blood cells

Long in the making changes lead to tipping point in blood stem cells

June 3, 2022
By Nuala Moran
Two studies published back to back in Nature have looked at the accumulation of mutations in blood-forming stem cells with age, gaining new insights into how the overall landscape of such cells changes across the lifespan. 
Read More
Scientists in lab

IDH1 mutations affect antitumor immunity in glioma

Oct. 1, 2021
By Anette Breindl
Low-grade gliomas with mutated isocitrate dehydrogenase-1 (IDH1) produced and secreted higher levels of the cytokine granulocyte colony-stimulating factor (G-CSF) than other glioma types, which improved their antitumor immune response in animal models.
Read More
KRAS protein

KRAS just wants to help: Pancreatic KRAS mutations may be protection gone bad

Sep. 17, 2021
By Anette Breindl
Investigators at MD Anderson Cancer Center have published data suggesting that activating KRAS mutations may be selected for in pancreatitis, because they protect pancreatic tissue from damage.
Read More
Human cell illustration

Mutational profiling gives clues to development, new puzzles about disease

Aug. 25, 2021
By Nuala Moran
The family trees of different cell types from different tissues and organs have been traced back to the fertilized egg that gave rise to the human body of which the cells formed a part, establishing a baseline for “normal” development and aging that could help improve understanding of the onset of disease.
Read More
Previous 1 2 3 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 1, 2026.
  • Floating antibody drug conjugates

    TROP2 ADCs progress into first-line for lung, breast cancers

    BioWorld
    Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...
  • Illustration of antibodies and viral infection

    New evidence links autoimmunity to long COVID symptoms

    BioWorld
    Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...
  • Liver with hepatitis viruses, blood cells

    Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections

    BioWorld
    GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...
  • Healthy (left) vs. cancerous bone marrow

    BMS’ mezigdomide doubles PFS in multiple myeloma

    BioWorld
    Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing